Trial Profile

Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Filgrastim (Primary)
Indications Neutropenia
Focus Therapeutic Use
Sponsors Sandoz

Most Recent Events

04 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Dec 2015.
27 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Dec 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com